A number of other equities analysts also recently commented on the stock. UBS Group reissued a buy rating on shares of Merck KGaA in a research note on Monday, January 15th. JPMorgan Chase & Co. set a €100.00 ($123.46) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, December 12th. Kepler Capital Markets set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, January 17th. Nord/LB reaffirmed a neutral rating on shares of Merck KGaA in a report on Wednesday, December 27th. Finally, Sanford C. Bernstein set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, January 17th. Twelve equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of €102.86 ($126.99).
Merck KGaA (FRA:MRK) opened at €78.74 ($97.21) on Friday. The company has a market cap of $10,210.00 and a P/E ratio of 13.17. Merck KGaA has a 12 month low of €76.60 ($94.57) and a 12 month high of €115.00 ($141.98).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.